A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Trial ID or NCT#

NCT02161406,

Status

not recruiting iconNOT RECRUITING

Purpose

The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score \[mRSS\]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.

Official Title

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Lorinda Chung
Lorinda Chung
Rheumatologist, Immunologist
Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Dermatology

View on ClinicalTrials.gov